Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

433
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
433
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

578
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
578
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

341
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
341
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study.

Intestinal research·2026
Same author

Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials.

Intestinal research·2026
Same author

A Rare Case of Ileoileal Fistula Concomitant with Adenocarcinoma in a Patient with Crohn's Disease.

Inflammatory intestinal diseases·2026
Same author

Inflammasomes in Intestinal Inflammation: Guardians of Mucosal Homeostasis, Amplifiers of Disease, and Targets for Intervention.

Internal medicine (Tokyo, Japan)·2026
Same author

Long-term drug persistence and clinical outcomes of ustekinumab in Crohn's disease: a multicenter real-world study from the Hokkaido phoenix cohort.

Crohn's & colitis 360·2026
Same author

Short- and Long-Term Effectiveness and Safety of Vedolizumab in Crohn's Disease: A Multicenter Retrospective Study from the Hokkaido Phoenix Cohort.

Inflammatory intestinal diseases·2026

Related Experiment Video

Updated: Mar 9, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

676

Heparin bridge therapy and post-polypectomy bleeding.

Toshiyuki Kubo1, Kentaro Yamashita1, Kei Onodera1

  • 1Toshiyuki Kubo, Kentaro Yamashita, Kei Onodera, Tomoya Iida, Hiroshi Nakase, Department of Gastroenterology and Hepatology, Sapporo Medical University, Sapporo 0608543, Japan.

World Journal of Gastroenterology
|December 27, 2016
PubMed
Summary
This summary is machine-generated.

Patients taking anticoagulants face a higher risk of post-polypectomy bleeding (PPB), even after stopping medication. Heparin bridge therapy may further increase this risk.

Keywords:
AnticoagulantsAntiplateletsColonic polypectomyEndoscopic surgeryHeparin bridge therapyPost-polypectomy bleeding

More Related Videos

Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

14.2K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K

Related Experiment Videos

Last Updated: Mar 9, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

676
Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

14.2K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K

Area of Science:

  • Gastroenterology
  • Endoscopy
  • Pharmacology

Background:

  • Post-polypectomy bleeding (PPB) is a significant complication following endoscopic procedures.
  • Identifying risk factors is crucial for preventing PPB and improving patient safety.

Purpose of the Study:

  • To determine risk factors for post-polypectomy bleeding (PPB).
  • To specifically evaluate the role of antithrombotic agents, including anticoagulants and antiplatelet drugs, in PPB.

Main Methods:

  • A case-control study was conducted using medical records from a single center.
  • Included 788 patients undergoing colonoscopic polypectomies, resections, or dissections between 2011 and 2014.
  • Evaluated patient-related factors (anticoagulants, antiplatelets, heparin bridge) and polyp/procedure-related factors.

Main Results:

  • PPB occurred in 3.7% of cases.
  • Anticoagulants and anticoagulant plus heparin bridge therapy were significant risk factors for PPB (P < 0.0001).
  • Antiplatelet agents and antiplatelet plus heparin therapy were not significantly associated with PPB.

Conclusions:

  • Patients on anticoagulant therapy have an elevated risk of PPB, irrespective of pre-procedure interruption.
  • Heparin bridge therapy may contribute to the increased PPB risk in patients taking anticoagulants.